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ABSTRACT 
Objective: The aim of the present study is to develop solid lipid nanoparticles (SLNs) of Nimodipine using hot homogenization followed by 
ultrasonication technique and to improve the dissolution characteristics of the drug.  
Methods: The Nimodipine-loaded SLN was prepared using palmitic acid and stearic acid as a lipid matrix and Tween-80 as an emulsifier by a hot 
homogenization and ultra-sonication method. The physicochemical characteristics of SLN were investigated for entrapment efficiency, zeta 
potential, in vitro drug release, particle size analysis, Fourier transform infrared studies, scanning electron microscopy, and stability studies.  
Results: The mean particle size, PDI, Zeta potential and entrapment efficiency of optimized Nimodipine SLN formulation of stearic acid was found to 
be 119.54 nm, 0.165,-17.60mV, 85% and for palmitic acid was found to be 132.54 nm, 0.155,-17.0mV, 81% respectively. In vitro drug release studies 
indicated that after an initial burst release, SLN could provide prolonged release of Nimodipine. The selected SLNs have shown good stability for a 
period of 180 d. 
Conclusion: SLN formulations showed the best results in EE as well as in vitro drug release and therefore, these results indicate that SLN might be a 
promising delivery system to enhance the release of Nimodipine. 
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INTRODUCTION 
Solid lipid nanoparticles introduced in 1991 represent an alternative 
carrier system to tradition colloidal carriers such as emulsions, 
liposomes and polymeric nanoparticles [1]. Nanoparticles made 
from solid lipids are attracting major attention as novel colloidal 
drug carriers for intravenous applications as they have been 
proposed as an alternative particulate carrier system. The system 
consists of spherical solid lipid particles in nanometre ranges, which 
are dispersed in water or in aqueous surfactant solutions. Generally, 
they are made of the solid hydrophobic core having a monolayer of 
phospholipid coating. The solid core contains the drug dissolved or 
dispersed in the solid high melting fat matrix. The hydrophobic 
chains of phospholipid are embedded in the fat matrix [2, 3]. The 
solid lipid nanoparticles are sub-micron colloidal carriers from 50-
1000 nm, which are composed of physiological lipid, dispersed in 
water or in aqueous surfactant solution. SLN offers unique 
properties such as small size, large surface area, high drug loading, 
and interaction of phases at the interface and attractive for their 
potential to improve the performance of pharmaceuticals [4]. Solid 
lipid nanoparticles (SLN) are at the forefront of the rapidly 
developing field of nanotechnology with several potential 
applications in drug delivery and research. Due to their unique size-
dependent properties, lipid nanoparticles provide the possibility to 
develop newer therapeutics. The ability to incorporate drugs into 
nanocarriers offers a new prototype in drug delivery that could use 
for drug targeting [5, 6]. Solid lipid nanoparticle is an efficient lipid-
based drug delivery system which can improve the bioavailability of 
poorly water-soluble drugs. Nimodipine, a potent antihypertensive 
agent has been used in the treatment of hypertensive disorders. 
Nimodipine is a highly lipophilic drug and poorly water-soluble drug 
with the bioavailability of 13%. The present work illustrates the 
development of an SLN formulation for Nimodipine with increased 
bioavailability [7, 8]. NSLNs were developed using Stearic acid, 
Palmitic acid as the lipid and Tween 80 as the surfactant by hot 
homogenization followed by an ultra-sonication method. NSLN’s 
were characterized for Scanning and Transmission Electron 
Microscopy (SEM), Entrapment Efficiency (EE), Stability studies and 
Zeta Potential.  
In vitro drug release studies were performed in pH 7.4 phosphate 
buffer. SLN formulation F4 and A4 composed of Tween 80 as a 
surfactant and lower concentration of lipid matrix (1000 mg of 
stearic acid for F4 and 1000 mg of Palmitic acid for A4) showed the 
best result in view of the entrapment efficiency as well as in vitro 
drug release; also the potential zeta studies showed that the formed 
particles were in Nano size and possess a negative surface charge.  
MATERIALS AND METHODS 
Materials 
Nimodipine was purchased from Shreeji Pharma International, 
Vadodara, Gujarat and stearic acid is purchased form Lobachemi 
Mumbai, Tween 80 and Palmitic acid were purchased from Sisco 
research Mumbai. The reagents used in this work all are analytical 
reagent grade. 
Methods 
Selection of lipids  
The solubility of Nimodipine was determined by dissolving an 
excess amount of drug in 200 mg of lipids (Palmitic acid, Stearic acid, 
Glyceryl monostearate, Glyceryl monooleate, cetyl palmitate, and 
cholesterol) in 5 ml stoppered vial and then the mixture was mixed 
by using a vortex mixer. For equilibrium, the vials were then kept at 
37±1.0 °C in an isothermal shaker (EXPO HI-TECH) for 72 h. The 
drug was added in increments of 10 mg. The quantity after which no 
further solubilization of drug was taken endpoint of solubilization. 
The equilibrated samples were transferred to a centrifuged tube and 
rotated at 3500 rpm for 15 min. The supernatant layer obtained 
from centrifuge was filtered through a 0.45 μm membrane filter. The 
concentration of drug was determined in each component by UV 
spectrophotometer. 
Selection of surfactants 
With the selected lipid, nanoparticles are prepared using different 
surfactants and were evaluated with respect to the particle size, PDI and 
entrapment efficiency. Selection of the surfactants was based on 
minimum particle size and PDI with maximum entrapment efficiency. 
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Preparation of SLNs  
The SLNs were produced using the modified high shear homogenization 
and ultra-sonication technique [9, 10]. SLN was prepared by heating 
different concentrations of lipids (stearic acid and palmitic acid) and 
different concentrations of surfactants (1% and 2%). The organic phase 
containing stearic acid and soya lecithin is added with the drug 
Nimodipine and heated to a temperature of 70 °C until it dissolves 
completely and heating the aqueous phase containing surfactant tween 
80 to the same temperature. The hot aqueous phase is added to the oil 
phase mixture and homogenized by using mechanical stirrer for 30 min 
to get a clear solution. It is then followed by probe sonication for 25 min 
[11, 12]. This similar technique used for preparing SLN with palmitic 
acid. In table 1 SLNs formulation data was given. 
 



























100 100 100 100 100 100 100 100 100 100 100 100 
Stearic Acid 1500 1500 1000 1000 500 500 - - - - - - 
Palmitic Acid - - - - - - 1500 1500 1000 1000 500 500 
Tween 80(ml) 1 2 1 2 1 2 1 2 1 2 1 2 
Soya lecithin  500 500 500 500 500 500 500 500 500 500 500 500 
Distilled 
water(ml) 
100 100 100 100 100 100 100 100 100 100 100 100 
 
Characterization of nimodipine SLNs 
Scanning electron microscopy (SEM) of nanoparticles 
The morphology of nanoparticles was investigated by SEM (SE S-
3400N; HITACHI, Japan). Briefly, 10 mg freeze-dried SLN was 
suspended in 1 ml distilled water and 2μl of the suspension was 
placed on a glass surface. After oven-drying, the samples were 
coated with gold using an Ion Sputter and examined at an 
accelerating voltage of 20 kV [13, 14]. 
Particle shape and surface morphology by transmission 
electron microscopy (TEM) 
Transmission electron microscopy (TEM) analysis of the prepared 
SLNs was carried out to study morphology like sphericity and 
aggregation. Sample was examined by TEM (H 100, Hitachi Ltd., 
Japan). Samples were stained with phosphotungstic acid (PTA, 2%,5 
min and excess PTA removed, spread on a grid and examined [15]. 
Particle size and zeta potential determination  
The average particle size, polydispersity index, and zeta potential of 
the lipid particulate dispersions were performed using a zeta sizer 
(DTS Ver.5.10, Malvern Instruments). The dispersion was diluted to 
1:10 v/v with double distilled water (filtered through 0.45 μm 
membrane filters) to determine that the light scattering intensity 
was within the instrument’s sensitivity range [16, 17]. 
Fourier transformed infrared (FTIR) spectroscopic analysis  
An FT-IR spectroscopy study has been carried out to check the 
compatibility between the drug (Nimodipine) and the lipid (SA and 
PA) separately, which are used for the preparation of nanoparticles. 
The FT-IR was performed for drug, lipids, and physical mixture of 
drug and lipid at a wavelength from 4000 to 400 cm-1 [18].  
Entrapment efficiency of the Nimodipine drug 
The centrifugation method was used for measuring the entrapment 
efficiency of the SLN dispersion [19, 20]. Supernatant liquid was 
collected by centrifuging the SLN dispersion (containing the 1 mg of 
Nimodipine drug) at 2000 rpm for one hour and then it was filtered 
to determine the free drug concentration. For the dilution of the 
sample, phosphate buffer saline with pH 7.4 was used. The 
absorbance was determined at 236 nm with a UV 
spectrophotometer and the entrapment efficiency was calculated 
using the equation (1). 




In vitro dug release 
The in vitro drug release of different dispersions of SLNs were 
determined using the dialysis bag technique. SLN dispersion 
containing an equivalent of 5 mg Nimodipine drug was transferred 
to the dialysis bag and the bag was sealed tightly. The sealed bag 
was suspended in the phosphate buffer saline and stirred with the 
help of a magnetic stirrer [21, 22]. The conditions for the suspended 
solution were pH 7.4 and the temperature of 37 °C±0.5 °C. After that, 
up to 12 h, aliquots were withdrawn at different time periods and 
the quantity of drug released was calculated by using the 
spectrophotometric studies at 236 nm.  
Stability studies 
The samples with high entrapment efficiencies were identified; for 
them Stability studies were conducted at two different temperatures 
of 4 °C and 25±2 °C. The drug content was measured for every 15 d 
to note the changes in the prepared SLNs. 
RESULTS 
Solubility studies 
The solubility of Nimodipine was determined by dissolving an excess 
amount of drug in 200 mg of lipids (Palmitic acid, Stearic acid, Glyceryl 
monostearate, Glyceryl monooleate, Cetyl palmitate, and cholesterol) in 
5 ml stoppered vial and then the mixture was mixed by using vortex 
mixer. The supernatant layer obtained from centrifuge was filtered 
through a 0.45 μm membrane filter. The concentration of the drug was 
determined at 236 nm for each component by UV spectrophotometer. 
The lipids Palmitic acid and Stearic acid given with higher solubility 
values when compared with other lipids and therefore, these lipids are 
used for further studies as shown in fig. 1. 
 
Table 2: Solubilization of nimodipine in various lipids 
S. No. Lipids Solubility(mg/gm) 
1 Glyceryl monostearate  90±12 
2 Glyceryl monooleate 70±10 
3 Cetyl palmitate 60±11 
4 Stearic acid 120±12 
5 Palmitic acid 100±11 
6  Cholesterol 80±11 
mean.±SD (n=3) 
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Fig. 1: Solubility profile of nimodipine in various lipids [mean.±SD (n=3)] 
 
Selection of surfactants 
The selected lipids (Palmitic acid and Stearic acid) are chosen for 
preparing nanoparticles using different grades of surfactant Tween 
(20.40.80) and were evaluated with respect to the particle size, PDI 
and entrapment efficiency. The surfactant Tween 80 was selected 
based on its minimum particle size and PDI and with maximum 
entrapment efficiency. 
 
Table 3: Selection of surfactants on the basis of particle size, PDI and entrapment efficiency for the drug nimodipine using lipid stearic 
acid and palmitic acid 
S. No. Lipid(1 gm/ml) Surfactant (1%) Particle size (nm) PDI Entrapment efficiency (%) 
1 Stearic acid Tween20 231.32±3.93 0.174±0.066 67.73±4.57  
2 Stearic acid Tween40 301.41±3.96 0.290±0.037 56.35±5.67  
3 Stearic acid Tween80 133.11±1.96 0.169±0.068 72.64±4.85  
4 Palmitic acid Tween20 265.01±2.92 0.222±0.057 65.73±8.49  
5 Palmitic acid Tween40 239.30±3.49 0.196±0.053 51.85±3.78  
6 Palmitic acid Tween80 158.01±3.98 0.122±0.052 75.66±6.35  
 mean.±SD (n=3) 
 
Particle sizes and zeta potentials 
All the prepared formulations were analyzed to determine their particle 
size distributions and zeta potential values. The results obtained after 
particle size analysis are shown in table 4. In all the formulations 
prepared using stearic acid had shown the particle sizes ranged from 
119 to 138 nm, and zeta potential-17mV to-37.6mV and polydispersity 
index was found to be between 0.162 to 0.265 (table 4) for formulations 
(F1 to F6). In all the formulations prepared using palmitic acid had 
shown the particle sizes ranged from 132 to 158 nm, and zeta potential-
17mV to-34.6mV and polydispersity index was found to be between 
0.155 to 0.275 (table 4) for formulations (A1 to A6). 
 















PDI Zeta potential 
(mV) 
F1 1500 1  81.8±1.55 76.1 138.71±2.95 0.162±0.02 -19.6±5.045 
F2 1500 2 83.8±1.35 81.5 122.2±4.13 0.174±0.055 -18.4±6.055 
F3 1000 1 82.4±4.35 80 133.11±3.93 0.169±0.046 -19.4±7.330 
F4 1000 2 85.8±2.45 83 119.3±1.89 0.165±0.044 -17.6±4.065 
F5 500 1 80.3±2.45 78 122.4±1.89 0.265±0.034 -27.6±4.065 
F6 500 2 81.2±2.45 80 121.64±1.89 0.205±0.064 -37.6±4.065 
A1 1500 1 79.5±0.45 80 133.9±3.96 0.171±0.052 -18.2±5.054 
A2 1500 2 80.9±0.55 81 132.4±2.23 0.170±0.056 -18.5±8.050 
A3 1000 1 80.7±2.30 83 135.0±3.93 0.163±0.058 -19.0±9.450 
A4 1000 2 81.8±3.45 85 132.6±3.93 0.155±0.052 -17.0±7.055 
A5 500 1 76.8±3.45 78 158.6±2.96 0.245±0.052 -34.0±7.055 
A6 500 2 79.8±3.45 80 149.6±3.93 0.275±0.022 -28.0±7.055 
 mean.±SD (n=3) 
 
IR studies 
Sample and total mixture were studied by using IR spectral studies. 
The FT-IR spectrums of pure drug Nimodipine and formulation are 
shown in fig. 2, respectively. Samples retained their individual 
absorption characteristics, without undergoing any interaction with 
one another. From these studies, we can conclude that no untoward 
chemical reactions were observed. 
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Fig. 2: Infrared spectrum of nimodipine and formulations 
 
Entrapment efficiency 
In table 4 the entrapment efficiency (responses) of the designed 
formulations was given. Entrapment efficiency was used to 
characterize the SLNs. The optimal encapsulation efficiency can 
decided by several factors like the concentration of the lipids and 
surfactants. From table 4, the entrapment efficiency was in the range 
of 81.2-85.8% for all formulations (F1toF6) and 76.8–81.8% for 
formulations (A1 to A6). This observation leads the statement that 
the decrease in the concentration of the lipid and increase in the 
concentration of the surfactant shows an increase in entrapment 
efficiency. F4 shows an entrapment efficiency of 85.8% and A4 
shows 81.8% entrapment. Drug expulsion in SLN can occur when 
the lipid matrix transforms from high energy modifications 
characterized by the presence of many imperfections with forming a 
perfect crystal with no room for guest molecules. Palmitic acid-lipid 
molecules are chemically different, resulting in a structure with 
many imperfections to accommodate the drug and thus higher 
loading capacity. About 80% of entrapment efficiency is seen in all 
formulations. Due to the low content of lipid in formulation showed 
more drug release. 
In vitro drug release  
Percentage release of drug with different concentrations of lipid 
stearic acid and the lipid palmitic acid are shown in table 4 
respectively. In vitro release profiles for Nimodipine for lipid stearic 
acid and the lipid palmitic acid were shown in fig. 3 and in fig. 4. Fig. 
3 shows that the in vitro studies of all the batches of stearic acid 
showed initial progress of 17%-30% of drug release for all the 
batches within 1hour and the 60% was released slowly over a 
period of 4 h. The batches F1-F6 shows about 80% of the 
Nimodipine drug was released at the end of 12 h. From the fig. 4 it 
was observed that A4 shows a drug release of 85% at the end of 
12hours and it is the highest compared to other lipid palmitic acid 
batches. All experiments were done in triplicate and values are 
expressed in means and standard deviation. In summary, an 
increase in drug release with increase in surfactants was observed. 
Morphological studies 
The SEM images for the SLNs loaded with nimodipine drugs were 
shown in fig. 5 and in fig. 6. From the morphological studies, it is 
revealed that the SLNs were in spherical shape. 
 
 
Fig. 3: In vitro release profile of nimodipine for different batches of drug-loaded with tween 80 and stearic acid [mean.±SD (n=3)] 
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Fig. 4: In vitro release of Nimodipine for different batches of drug-loaded with Tween 80 and palmitic acid [mean.±SD (n=3)] 
 
 
Fig. 5: Scanning electron microscopy of nimodipine SLN F4 (Containing tween 80, stearic acid and drug concentration–100 mg) 
 
 
Fig. 6: Scanning electron microscopy of nimodipine SLN A4 (Containing tween 80, palmitic acid and drug concentration–100 mg) 
 
 
Fig. 7: Transmission electron microscopy of nimodipine SLN F4 (Containing Tween 80, stearic acid and drug concentration–100 mg) 
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Fig. 8: Transmission electron microscopy of nimodipine SLN A4 (Containing tween 80, palmitic acid and drug concentration–100 mg) 
 
Stability studies 
For the samples with high entrapment efficiencies, stability studies 
were conducted. The temperatures maintained were 4 °C and 25 
°C±2 °C and the time for the study was 180 d. Stability studies 
identified that the SLNs were physically stable. 
DISCUSSION 
Nimodipine solid lipid nanoparticles were prepared by hot 
homogenization technique followed by ultrasonication. The method 
was able to produce nanoparticles of an acceptable range. FT-IR 
spectroscopic studies were conducted to determine possible drug: 
lipid interactions. FT-IR spectrum of pure drug nimodipine, stearic 
acid, palmitic acid and physical mixture of nimodipine with stearic 
acid, palmitic acid tween80 were obtained and shown in fig. 2. The 
characteristic peaks of nimodipine and lipids were also present in 
the spectra of physical mixtures, thus indicating that there is no 
significant evidence of chemical interaction between drug and lipids. 
The SLNs were characterized for average particle size, PDI, zeta 
potential and percentage drug entrapped efficiency. The formulation 
resulted in consistent nanoparticles of narrow size distribution and 
bring about a slight increase in particle sizes from 119.32±39.93 to 
138.71±30.95 nm for formulation F1 to F6 and 132 nm to 158 nm 
for formulation (A1-A6). These findings are in reliable with the 
study of Jensen et al. [21] who explained that the increase in size of 
SLNs after integration of drug replicated the dissolution of the drug 
in the lipid phase. A narrow particle size distribution was a sign of 
nanoparticles stability and homogeneous dispersion [22]. Zeta 
potential of various nimodipine loaded SLNs with stearic acid varies 
from-17.6 to-37.6 mV and the polydispersity index was found to be 
between 0.162 to 0.265 (table 4). Zeta potential of various 
nimodipine loaded SLNs with palmitic acid varies from-17.6 to-34 
mV and polydispersity index was found to be between 0.155 to 
0.275 (table 4). PDI values ranging from 0 to 0.5 were measured to 
be monodisperse and homogenous, but those of more than 0.5 
indicated non-homogeneity and polydispersity [23]. In the present 
study, the particle size distribution was monodisperse and 
homogenous as formulation has less mean±standard error PDI of 
0.17±0. According to Schwarz and Mehnert [22] and Zimmermann et 
al. [24], the negative charge of zeta potential was deliberated by the 
lipids used in the SLNs. In a pact with this, the PA utilized in this 
study provided a negative charge of zeta potential. Nanoparticle 
with zeta potential values>+25 mV or<−25 mV usually has high 
degrees of stability due to electric repulsion between particles. 
Dispersions with a low zeta potential value will aggregate due to Van 
Der Waal inter-particle attraction [25]. In this study, the mean±SD 
zeta potential of −14.2±1.00. These SLNs of stearic acid (F1–F6) 
presented drug entrapment efficiency of 81.2% to 85.80% and that 
of palmitic acid (A1–A6) shown 76.8-81.8% which is due to its 
lipophilic nature (table 4). In vitro drug release study was executed 
for all the formulations SLN F1 to SLN F6 of 76.1 to 83% and SLN A1 
to SLN A6, which shows the sustained release of drug of about 78-
85% respectively after 12 h. The initial release should be sufficiently 
rapid to confirm that the therapeutic drug levels are attained in a 
timely manner in vivo. The subsequent slow release is mainly due to 
the slow diffusion of drug molecules through the lipid matrix of the 
nanoparticles [24, 25]. Slow drug release will contribute to 
maintaining the effective therapeutic drug concentrations. The 
optimized Nimodipine SLNs were preferred as SLNs F4 and A4 
which shows a least zeta potential and good EE. As the concentration 
of surfactant mixture is increased exhibited smallest particle size 
and it has been found out that Tween 80 promotes the formation of 
smaller sized nanoparticles and were observed that increased 
content of surfactant supports the formation of smaller 
nanoparticles [25]. All the SLNs formulations showed negative zeta 
potential values, which indicate the stable nature of nanoparticles 
due to electrostatic repulsion. As the surfactant content increased, 
EE increases, which could be due to the development of stabilized 
nanoparticles. This increase in solubility is probably responsible for 
an increase in the drug release in acid medium and increased lipid 
content reduced the cumulative release, which is in consistent with 
the earlier reports. The lipid content increases the packing density of 
lipid molecules in given space as a result of release is reduced. For 
further studies, based on the particle size, PDI, zeta potential, and in 
vitro release, F4 and A4 was considered 
CONCLUSION 
In this work, the Nimodipine drug was successfully loaded into SLNs 
by modified high shear homogenization and ultra-sonication 
techniques. The effects of different formulation variables on 
percentage entrapment efficiency and physiochemical properties were 
evaluated. The in vitro release tests showed that the slow release of 
drug release. The type and concentration of surfactant, as well as the 
lipid matrix, were played a greater role on physicochemical 
characterization of SLNs and the in vitro drug release. SLN formulation 
F4 and A4 composed of Tween 80 as a surfactant with higher 
concentration and the lower concentration of lipid matrix (1000 mg of 
stearic acid for F4 and 1000 mg of palmitic acid for A4) showed the 
best result in view of the entrapment efficiency as well as in vitro drug 
release. Particle size analysis showed that the formed particles were in 
Nano size. Based on observation, it can be concluded that the 
formulated lipid Nanoparticulate delivery system of Nimodipine could 
be widely accepted and physiologically safe lipids were capable of 
exhibiting sustained properties. In conclusion, the SLNs designed in 
this work were shown efficient drug delivery systems for poor soluble 
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